Skip to content

Mepolizumab exposure and blood eosinophils

A coupled subcutaneous or intravenous PK/PD model linking mepolizumab absorption and distribution to concentration-dependent suppression and turnover of circulating eosinophils.

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab ↗

Int. Journal of Clinical Pharmacology and Therapeutics

Exploration notes · What are you exploring?

Notes stay on this browser.

MODEL IN MOTION 18 sec

How does increasing the SC dose change the eosinophil response?

Run settings

Run location

Explore this model

Choose a scenario, adjust inputs, and run the simulation.

12.5 mg SC every 4 weeks, three doses

How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?

0–140 day

Scenario details

12.5 mg SC every 4 weeks, three doses

How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?

Readouts

Mepolizumab concentration · Unit unavailable
Mepolizumab concentration over the selected simulation window.
Blood eosinophil concentration · Gcell/L
Blood eosinophil concentration over the selected simulation window.
Eosinophil inhibition · Unit unavailable
Eosinophil inhibition over the selected simulation window.
Exposure (AUC) · ug*day/mL
Exposure (AUC) over the selected simulation window.

Study purpose

  • How do route and dose change mepolizumab exposure and the depth and duration of eosinophil suppression?

Inputs changed since the displayed result. Run to update the comparison.

Loading starting example…

Edit inputs

Model parameter

Clearance intravenous governing removal of modeled material from the relevant compartment.

L/day

Suggested: 0.105–0.315. You can explore beyond this range.

0.21 → —

Central distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.

L

Suggested: 1.8–5.4. You can explore beyond this range.

3.6 → —

Absorption rate constant governing entry from the administration site.

1/day

Suggested: 0.097–0.291. You can explore beyond this range.

0.194 → —

Half-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.

ng/mL

Suggested: 631–1,890. You can explore beyond this range.

1261 → —

Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.

—

Suggested: 0.464–1.39. You can explore beyond this range.

0.928 → —
Simulation time
day
day
140 → 168

Time between reported samples.

day

1 change · Variation 1

Continue in the background and keep the result.

Biology

Subcutaneous mepolizumab passes through a depot before entering central exposure, while intravenous input enters the central compartment directly. Central and peripheral drug exchange and central drug undergoes weight-scaled clearance. Systemic concentration empirically inhibits eosinophil production, while circulating eosinophils undergo first-order turnover.

How do subcutaneous or intravenous mepolizumab exposure and an empirical inhibition term change circulating eosinophils?Subcutaneous mepolizumab passes through a depot before entering central exposure, while intravenous input enters the central compartment directly. Central and peripheral drug exchange and central drug undergoes weight-scaled clearance. Systemic concentration empirically inhibits eosinophil production, while circulating eosinophils undergo first-order turnover.BIOLOGY OVERVIEWHow do subcutaneous or intravenous mepolizumab exposure and an empiricalinhibition term change circulating eosinophils?SC or IV regimen: Mepolizumab administrationSC or IV regimenMepolizumab administrationSubcutaneous depot: Bioavailable first-order absorptionSubcutaneous depotBioavailable first-orderabsorptionSystemic mepolizumab: Central ↔ peripheral PKSystemicmepolizumabCentral ↔ peripheral PKDrug clearance: Weight-scaled central lossDrug clearanceWeight-scaled central lossEosinophil production: Empirically inhibited by exposureEosinophilproductionEmpirically inhibited byexposureBlood eosinophils: Circulating cell countBlood eosinophilsCirculating cell countEosinophil turnover: First-order cell lossEosinophilturnoverFirst-order cell lossPRIMARY READOUTSCentral mepolizumabCentral mepolizumabBlood eosinophilsBlood eosinophilsEosinophil inhibitionEosinophil inhibitionCumulative exposureCumulative exposure

Solid arrows show modeled movement or change; two-headed arrows show reversible exchange; dashed arrows show modulation without material transfer.

Model scope: Explicit IL-5 concentration, mepolizumab–IL-5 binding or occupancy, bone-marrow or tissue eosinophil pools, trafficking, asthma symptoms, and clinical response are not represented. IL-5 is therapeutic context only; the runtime applies empirical concentration-dependent inhibition directly to circulating-eosinophil production.

Modeled relationships (7)
  • SC or IV regimen → Subcutaneous depot: SC bolus (flow)
  • SC or IV regimen → Systemic mepolizumab: IV input (flow)
  • Subcutaneous depot → Systemic mepolizumab: Fsc · KA (flow)
  • Systemic mepolizumab → Drug clearance: weight-scaled CL (loss)
  • Systemic mepolizumab → Eosinophil production: Hill inhibition (modulation)
  • Eosinophil production → Blood eosinophils: baseline production (production)
  • Blood eosinophils → Eosinophil turnover: KOUT loss (loss)

Modeled relationships: SC or IV regimen to Subcutaneous depot: SC bolus (flow); SC or IV regimen to Systemic mepolizumab: IV input (flow); Subcutaneous depot to Systemic mepolizumab: Fsc · KA (flow); Systemic mepolizumab to Drug clearance: weight-scaled CL (loss); Systemic mepolizumab to Eosinophil production: Hill inhibition (modulation); Eosinophil production to Blood eosinophils: baseline production (production); Blood eosinophils to Eosinophil turnover: KOUT loss (loss).

Primary readouts: Central mepolizumab; Blood eosinophils; Eosinophil inhibition; Cumulative exposure.

Model details

15 parameters · 6 states · 6 equations · 21 derived outputs

Classification & API access
Therapeutic
Mepolizumab, Nucala
Modality
Monoclonal antibody
Target
IL5, IL-5
Disease / scope
Eosinophilic asthma
ParameterDefaultUnitDescription
Clearance intravenousCL_iv_L_day0.21L/dayClearance intravenous governing removal of modeled material from the relevant compartment.
F subcutaneousF_sc0.74—F subcutaneous coefficient used by the released system of model equations.
Half-maximal inhibitory concentrationIC50_ng_mL1261ng/mLHalf-maximal inhibitory concentration at which the corresponding modeled process is inhibited by half.
Imax fractionIMAX_fraction0.928—Imax fraction defining the limiting magnitude of the corresponding pharmacodynamic effect.
Absorption rate constantKA_1_day0.1941/dayAbsorption rate constant governing entry from the administration site.
Turnover loss rateKOUT_1_day0.4141/dayTurnover loss rate governing loss, degradation, or removal in the modeled biological process.
Kro baseline giKRO_baseline_GI_L0.71Gcell/LKro baseline gi coefficient used by the released system of model equations.
KcpKcp_1_day0.281/dayKcp coefficient used by the released system of model equations.
KpcKpc_1_day0.2831/dayKpc coefficient used by the released system of model equations.
Central distribution volume intravenousVc_iv_L3.6LCentral distribution volume intravenous used to convert modeled amount to concentration in the relevant compartment.
Body weightbody_weight_kg70kgBody weight used for body-size scaling in the model.
Hill slopehill_slope1—Hill slope coefficient used by the released system of model equations.
Reference weightreference_weight_kg70kgReference weight coefficient used by the released system of model equations.
Typical clearance weighttheta_cl_weight0.75—Typical clearance weight governing removal of modeled material from the relevant compartment.
Typical v weighttheta_v_weight1—Typical v weight coefficient used by the released system of model equations.

Related models

Befovacimab PK and TFPI target bindingEculizumab fixed PK and authored response diagnosticsRavulizumab PK and independent C5 decay coordinatesSecukinumab fixed PK and response-coordinate reference

Feedback: helpdesk@unibiointelligence.com.

Ubi Biologics